( udingtwo large multi-national Phase 3 ...)Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics,Health

uding two large multi-national Phase 3 studies in complicated skin and skin structure infections performed by former developers Lilly and InterMune, Inc. Targanta expects to file a New Drug Application (NDA) for oritavancin with the U.S. Food and Drug Administration in the second half of 2007.

About Targanta Therapeutics

Targanta Therapeutics is a privately held biopharmaceutical company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Its pipeline includes an array of antibacterial agents in various stages of development. The company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Canada. For further information about Targanta, visit the company website, http://www.targanta.com.

Disclaimer

All forward-looking statements and other information included in this press release are based on information available to Targanta as of the date hereof, and Targanta assumes no obligation to update any such forward-looking statements or information. Targanta's actual results could differ materially from those described in Targanta's forward-looking statements.

    (1) Centers for Disease Control and Prevention, Coordinating Center for

        Infectious Diseases / Division of Bacterial and Mycotic Diseases,

        http://www.cdc.gov/ncidod/dbmd/diseaseinfo/staphylococcus_food_g.htm


    (2) Centers for Disease Control and Prevention, Coordinating Center for

        Infectious Diseases / Division of Bacterial and Mycotic Diseases,

        http://www.cdc.gov/ncidod/dbmd/diseaseinfo/streppneum_t.htm

CONTACT: Gayle Crick Fischer, R.Ph. of Targanta Therapeutics,+1-317-502-2467; or Danette Berry of Spectrum Science C
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS